Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy

Overview of attention for article published in Journal of Hematology & Oncology, August 2016

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

So far, Altmetric has seen 18 patents that reference this research output.

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 14 additional patents.